NL-OMON32471尚未招募不适用
Relative aerobic load and energy cost of balance control in elderly people walking with a unilateral lower limb prosthesis - Relatieve aerobic load and balance control in amputee walking
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •For control participants
- •--> Participants are within between 50 and 75 years of age
- •--> Participants are able to walk for at least 4 minutes for 6 subsequent trials, between trials 20 minutes of rest is given to prevent fatigue.;For participants with amputation
- •--> The participants have acquired a walking ability of degree C-F on the SIGAM mobility grade [24, 25], indicating, that they participants are able to walk a minimum of 50 meters.
- •--> The participants are able to walk for at least 4 minutes for 6 subsequent trials, between trials 20 minutes of rest if given to prevent fatigue.
- •--> During the last minute of the trial the participant should be able to walk without support.
- •--> Time since amputation is more than 1 year.
- •--> Participants are comfortable with and accustomed to walk with their prosthesis.
排除标准
- •--> Abnormalities found in the resting ECG or blood pressure.
- •--> Problems noted by the physiatrist which could interfere with the results or the participants well being during the measurements.
- •--> Participant scoring less than 24 points out of the 30 that can be gained< 24/30 on the Modified Mini Mental State Examination questionnaire.
- •-->Neurological or musculoskeletal disorders which have an effect on the execution of gait other than disorders related to the amputation.
- •--> problems with the stump which could interfere with walking ability.
研究者
相似试验
招募中
不适用
The effects of intermittent fasting and high intensity interval training on body composition, markers of metabolic and cardiovascular health and micro ribonucleic acid (miRNA) expression in overweight/obese individualsMetabolic SyndromeDiet and Nutrition - ObesityMetabolic and Endocrine - Metabolic disordersObesityACTRN12615001331527Victoria University260
已完成
不适用
Do Making Habits or Breaking Habits Influence Weight Loss and Weight Loss Maintenance: A Randomised Controlled TrialObesityACTRN12615000114549Gina Cleo75
进行中（未招募）
不适用
A randomized, parallel group, open-label, active controlled, multicenter Phase III trial of Patupilone (EPO906) versus pegylated liposomal doxorubicin (Doxil/Caelyx) in taxane/platinum refractory/resistant patients with recurrent epithelial ovarian, primary fallopian or primary peritoneal canceradvanced epithelial ovarian cancerMedDRA version: 14.1Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2004-005181-20-ITOVARTIS FARMA810
进行中（未招募）
1 期
A randomized, parallel group, open-label, active controlled, multicenter Phase III trial of Patupilone (EPO906) versus pegylated liposomal doxorubicin (Doxil/Caelyx) in taxane/platinum refractory/resistant patients with recurrent epithelial ovarian, primary fallopian or primary peritoneal cancerApproximately 75% of women with ovarian cancer present advanced disease. Survival is highly dependent on the stage of disease at the initiation of treatment. Recommended first-line therapy is a combination of platinum drug and paclitaxel. Patients who progress during primary therapy or within 6 months after are considered platinum refractory/resistant. The prognosis of patients with resistant / refractory ovarian cancer is uniformly poor with median overall survival ranging from 35 – 41 weeksEUCTR2004-005181-20-GRovartis Pharma Services AG
进行中（未招募）
不适用
A randomized, parallel group, open-label, active controlled, multicenter Phase III trial of Patupilone (EPO906) versus pegylated liposomal doxorubicin (Doxil/Caelyx) in taxane/platinum refractory/resistant patients with recurrent epithelial ovarian, primary fallopian or primary peritoneal cancerApproximately 75% of women with ovarian cancer present advanced disease. Survival is highly dependent on the stage of disease at the initiation of treatment. Favorable prognostic factors include young age, cell type other than clear cell or mucinous, lower stage, good performance status, small residual tumor volume after surgery, and absence of ascites. The prognosis of patients with resistant / refractory ovarian cancer is uniformly poor with median overall survival ranging from 35 – 41 weeks.EUCTR2004-005181-20-HUovartis Pharma Services AG810